R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy
R. Lee Buckler
and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications.
RepliCel Life Sciences Inc.
(RP:TSX.V; REPCF:OTCQB) is tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin.
In this interview with The Life Sciences Report, R. Lee Buckler, the company's new vice president of business and corporate development, discusses his firm's innovative technology platform and the upcoming milestones that could affect its shares.
Management Q&A: View From the Top
The Life Sciences Report: Lee, you've made a recent career change and are now an executive at RepliCel.
Tell us about that.
R. Lee Buckler: As of Oct. 7, I have been appointed vice president of business and corporate development for RepliCel Life Sciences Inc., which is engaged in development of cell-based regenerative medicine therapeutics in Canada, Europe and Japan through our licensing partner, Shiseido Company Ltd. (4911:TSE).
TLSR: Thank you very much for your insight, Lee
RLB: Thank you.
R. Lee Buckler is vice president of business and corporate development with RepliCel Life Sciences Inc.
Prior to working with RepliCel, he was the managing director of Cell Therapy Group, a firm he formed in 2008, where he did business development consulting for companies and organizations in or interested in the cell therapy sector.
Buckler served six years as executive director of the International Society for Cellular Therapy, and just over two years as director of business development for Progenitor Cell Therapy.
He is on the editorial advisory boards of the journal Regenerative Medicine and the BioProcess International magazine, as well as the co-chair of the Alliance for Regenerative Medicine's Communications and Education Committee.
Buckler cofounded Cell Therapy News, founded Cell Therapy Blog, cofounded Regenerative Medicine Jobs, founded and continues to manage the LinkedIn Cell Therapy Industry Group, and is an active industry commentator in publications and in social media.
He serves on numerous industry conference advisory boards, is an advisory board member for BioCision and RoosterBio, and is on the board of directors for Hemostemix.
He has a bachelor's degree in education and a law degree.
3) R. Lee Buckler
had final approval of the content and is wholly responsible for the validity of the statements.
Opinions expressed are the opinions of R. Lee Buckler
and not of Streetwise Reports
or its officers.